Castle Biosciences Executive Compensation (FY25)
CSTL · Executive and director compensation, fiscal 2025 only
The Castle Biosciences brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 19, 2026Latest filing (8-K): May 29, 2026
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
148 figures on this page: 143 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
Frequently asked questions
Answers drawn from the data on this page.
Who is Castle Biosciences' chief executive and what were they paid?
Total compensation for Derek Maetzold, President and Chief Executive Officer, came to $6,786,771 in fiscal 2025.
What was Castle Biosciences' say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 94.3% support at the meeting held May 28, 2026.
Which companies are in Castle Biosciences' peer group?
The disclosed peer group includes Cytek Biosciences, Inc., GeneDx Holdings Corp., Invitae Corporation, Maravai Lifesciences Holdings, Inc. and Natera, Inc.
What is Castle Biosciences' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 51.9:1, against median employee compensation of $130,759.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Derek Maetzold President and Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Frank Stokes Chief Financial Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Tobin Juvenal Chief Commercial Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Kristen Oelschlager Chief Operating Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Derek J. Maetzold | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Derek J. Maetzold | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Frank Stokes | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Frank Stokes | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Kristen M. Oelschlager | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Kristen M. Oelschlager | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Tobin W. Juvenal | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Tobin W. Juvenal | RSU | ◇ | — | — | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Kristen Oelschlager | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Tobin Juvenal | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Frank Stokes | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Derek Maetzold | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Derek Maetzold
President and Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Frank Stokes
Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance cash amount | ◇ |
Kristen Oelschlager
Chief Operating Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance cash amount | ◇ |
Tobin Juvenal
Chief Commercial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance cash amount | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Rodney Cotton | ◇ | ◇ | — | — | — | — | ◇ |
Daniel M. Bradbury Board chair | ◇ | ◇ | — | — | — | — | ◇ |
G. Bradley Cole | ◇ | ◇ | — | — | — | — | ◇ |
Ellen Goldberg | ◇ | ◇ | — | — | — | — | ◇ |
Tiffany P. Olson | ◇ | ◇ | — | — | — | — | ◇ |
Miles D. Harrison | ◇ | ◇ | — | — | — | — | ◇ |
Kimberlee S. Caple | ◇ | ◇ | — | — | — | — | ◇ |
Derek J. Maetzold served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Cytek Biosciences, Inc. CKTB
- GeneDx Holdings Corp. WGS
- Invitae Corporation NVTAQ
- Maravai Lifesciences Holdings, Inc. MVRVI
- Natera, Inc. NTRA
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 28, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 22, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 23, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 25, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 2, 2022 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Castle Biosciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Castle Biosciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
148 figures on this page: 143 cited to the filing that reported them, 5 calculated from figures it prints.
143 cited to the filing
5 calculated from the filing
Documents cited
- 0001628280-26-039189Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001628280-26-024166CEO Pay Ratio · Compensation Discussion and Analysis · DIRECTOR COMPENSATION · Grants of Plan-Based Awards · and 3 more sections
- 0001447362-25-000085
- 0001447362-24-000072
- 0001447362-23-000095
- 0001447362-22-000109
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Castle Biosciences executive compensation, FY2025.” https://intel.velarion.ai/comp/CSTL (accessed 2026).
Short form: data: Velarion
The Castle Biosciences brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Castle Biosciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Castle Biosciences discloses
The companies named in CSTL's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}